Recombinant erythropoietin biosimilar - Recpharma

Drug Profile

Recombinant erythropoietin biosimilar - Recpharma

Alternative Names: EPOLYREC

Latest Information Update: 11 Jun 2015

Price : $50

At a glance

  • Originator Recpharma
  • Class Antianaemics; Erythropoietins; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 May 2015 Launched for Anaemia in Iran (IV) before May 2015
  • 19 May 2015 Launched for Anaemia in Iran (SC) before May 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top